Mark Clemons profile picture

Contact Information

Mark Clemons, MB BS, BMedSci, MSc, MD, FRCP, FRCPC
70170
mclemons@toh.ca

Division of Medical Oncology
The Ottawa Hospital Cancer Centre (Box 912)
501 Smyth Road
Ottawa ON
K1H 8L6

ORCID logo https://orcid.org/0000-0002-0738-2713

Publications

Selected Publications

Clemons M, Ong M, Stober, C, Ernst S, Booth C, Canil C, Mates M, Roberson A, Blanchette P, Joy AA, Hilton J, Aseyev O, Pond G, Jeong A, Hutton B, Mazzarello S, Vandermeer L, Kushnir I, Fergusson D. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Accepted Eur J of Cancer, August 2020. 

Clemons M, Fergusson D, Simos D, Mates M, Robinson A, Califaretti N, Zibdawi L, Bahl M, Raphael J, Ibrahim MFK, Fernandes R, Pitre L, Aseyev O, Stober C, Vandermeer L, Saunders D, Hutton B, Mallick R, Awan AA, Hilton J. A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. Ann Oncol 2020 Apr 20; S0923-7534(20)39296-6. doi: 10.1016/j.annonc.2020.04.005.

Basulaiman B, Awan AA, Fergusson D, Vandermeer Lisa, Arnaout A, Hilton J, Hutton B, Joy AA, Robinson A, Califaretti N, Stober C, Sienkiewicz M, Thavorn K, Clemons M. Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). Breast Cancer Res Treat. 2019 Aug;177(1):93-101.

Clemons M, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Segal R, Dent S, Gertler S, Song X, Wheatley-Price P, Dranitsaris G. A Randomized Trial Comparing Risk Model Guided Antiemetic Prophylaxis to Physician's Choice in Patients Receiving Chemotherapy for Early Stage Breast Cancer. JAMA Oncology. Accepted August 7, 2015. – Senior Responsible Author (Impact Factor NA)

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Res Treat. 2014 Mar 18. [Epub ahead of print] – Senior Responsible Author (Impact Factor 5.881)

Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. A prospective study evaluating the impact of tissue confirmation of metastatic disease in breast cancer patients. Journal of Clinical Oncology 2012;30(6):587-92 – Senior Responsible Author (Impact factor 17.7)


All Other Publications

Refereed Journal Articles

  1. Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B, Ibrahim MF, Jacobs C, Ong M, Clemons M. Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review. Support Care Cancer. 2015 Sep 19. [Epub ahead of print] PubMed PMID: 26386706.
  2. Hernandez Torres C, Mazzarello S, Ng T, Dranitsaris G, Hutton B, Smith S, Munro A, Jacobs C, Clemons M. Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience. Support Care Cancer. 2015 Jun 25. [Epub ahead of print] PubMed PMID: 26108169. – Senior Responsible Author (Impact Factor 2.49)
  3. Ng TL, Hutton B, Clemons M. Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea? Oncologist. 2015. pii: the oncologist.2014-0438. [Epub ahead of print] PubMed PMID: 25948677. – Senior Responsible Author. (Impact Factor 5.49)
  4. Clemons M, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Segal R, Dent S, Gertler S, Song X, Wheatley-Price P, Dranitsaris G. A Randomized Trial Comparing Risk Model Guided Antiemetic Prophylaxis to Physician's Choice in Patients Receiving Chemotherapy for Early Stage Breast Cancer. JAMA Oncology. Accepted August 7, 2015. – Senior Responsible Author (Impact Factor NA)
  5. Simos D, Catley C, van Walraven C, Arnaout A, Booth CM, McInnes M, Fergusson D, Dent S, Clemons M. Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. CMAJ. 2015 Jun 22. pii: cmaj.150003. [Epub ahead of print] PubMed PMID: 26100841. – Senior Responsible Author (Impact Factor 5.9)
  6. Sud S, Lai P, Zhang T, Clemons M, Wheatley-Price P. Chemotherapy in the oldest old: The feasibility of delivering cytotoxic therapy to patients 80years old and older. J Geriatr Oncol. 2015 Aug 13. pii: S1879-4068(15)00070-3. (Impact Factor 1.85)
  7. Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M, Gonzalez-Angulo AM, Joyce JA, De Palma M, Pollard JW, Lewis CE. Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Res. 2015 Aug 12. [Epub ahead of print] PubMed PMID: 26269531. (Impact Factor 9.32)
  8. Mazzarello S, Clemons M, Graham ID, Joy AA, Smith S, Jacobs C. Third-party online surveys-science, selling, or sugging? Curr Oncol. 2015 Jun;22(3):182-3. doi: 10.3747/co.22.2448. PubMed PMID: 26089716; PubMed Central PMCID: PMC4462527. (Impact Factor 2.47)
  9. Innominato PF, Lim AS, Palesh O, Clemons M, Trudeau M, Eisen A, Wang C, Kiss A, Pritchard KI, Bjarnason GA. The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer. 2015 Aug 11. [Epub ahead of print] PubMed PMID: 26260726. (Impact Factor 2.49)
  10. Ibrahim MF, Mazzarello S, Shorr R, Vandermeer L, Jacobs C, Hilton J, Hutton B, Clemons M. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol. 2015 Jun 28. pii: mdv284. [Epub ahead of print] Review. PubMed PMID: 26122727. (Impact Factor 7.04)
  11. Mazzarello S, Hutton B, Ibrahim MF, Jacobs C, Shorr R, Smith S, Ng T, Clemons M. Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat. 2015 May 24. [Epub ahead of print] PubMed PMID: 26003182. – Senior Responsible Author. (Impact Factor 5.49)
  12. Kuchuk M, Kuchuk I, Sabri E, Hutton B, Clemons M, Wheatley-Price P. The incidence and clinical impact of bone metastases in non-small cell lung cancer. Lung Cancer. 2015 May 11. pii: S0169-5002(15)00206-8. doi: 10.1016/j.lungcan.2015.04.007. [Epub ahead of print] PubMed PMID: 26003503. (Impact Factor 1.3)
  13. Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, Ibrahim MF, Gregario N, Daigle K, Eggert L, Clemons M. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients. Support Care Cancer. 2015 May 3. [Epub ahead of print] – Senior Responsible Author. (Impact Factor 2.49)
  14. Joy AA, Ghosh M, Fernandes R, Clemons MJ. Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines. Curr Oncol. 2015 Mar;22(Suppl 1):S29-42. (Impact Factor 2.47)
  15. Levasseur N, Clemons M, Hilton J, Addison C, Robertson S, Ibrahim M, Arnaout A. Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer? Minerva Chir. 2015 Jun;70(3):181-93. Epub 2015 Mar 4. PubMed PMID: 25737461. (Impact Factor 0.67)
  16. Arnaout A, Robertson S, Kuchuk I, Simos D, Pond GR, Addison CL, Namazi M,Clemons M. Evaluating the feasibility of performing window of opportunity trials in breast cancer. Int J Surg Oncol. 2015;2015:785793. doi: 10.1155/2015/785793. Epub 2015 Jan 20. PubMed PMID: 25685551. – Senior Responsible Author. (H index 7)
  17. Mazzarello S, Clemons M, Jacobs C, Arnaout A, Fralick M. Publishing clinical research: ten pearls for oncology trainees and junior oncologists. Curr Oncol. 2015 Feb;22(1):e1-5. doi: 10.3747/co.22.2258. PubMed PMID: 25684991. – Collaborator (Impact Factor 2.47)
  18. Mandilaras V, Bouganim N, Spayne J, Dent R, Arnaout A, Boileau JF, Brackstone M, Meterissian S, Clemons M. Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm? Curr Oncol. 2015;22(1):25-32.– Senior Responsible Author. (Impact Factor 2.47)
  19. Kanwar N, Hu P, Bedard P, Clemons M, McCready D, Done SJ. Identification of genomic signatures in circulating tumor cells from breast cancer. Int J Cancer. 2015 Jul 15;137(2):332-44. doi: 10.1002/ijc.29399. Epub 2015 Jan 12. PubMed PMID: 25529931. (Impact Factor 5.08)
  20. Jacobs C, Hutton B, Ng T, Shorr R, Clemons M. Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer?: A Systematic Review. The Oncologist. 2015;20(2):210-23 – Senior Responsible Author. (Impact Factor 5.49)
  21. Jacobs C, Graham ID, Makarski J, Chassé M, Fergusson D, Hutton B, Clemons M. Clinical practice guidelines and consensus statements in oncology - an assessment of their methodological quality. PLoS One. 2014 Oct 17;9(10):e110469. – Senior Responsible Author (Impact Factor 3.534)
  22. Addison CL, Pond GR, Zhao H, Mazzarello S, Vandermeer L, Goldstein R, Amir E, Clemons M. Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. Springerplus. 2014 Oct 1;3:577. – Senior Responsible Author (Impact Factor NA)
  23. Simos D, Hutton B, Graham ID, Arnaout A, Caudrelier JM, Clemons M. Imaging for metastatic disease in patients with newly diagnosed breast cancer: are doctor's perceptions in keeping with the guidelines? J Eval Clin Pract. 2014 Oct 14. [Epub ahead of print] – Senior Responsible Author (Impact Factor ) 
  24. Jacobs C, Ng T, Ong M, Clemons M. Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits. Curr Opin Support Palliat Care. 2014 Aug 13. [Epub ahead of print] PubMed PMID: 25121618. – Senior Responsible Author (H index 22 )
  25. Jacobs C, Clemons M. Thoughts on Jim Flaherty. When should physicians retire? Curr Oncol. 2014 Aug;21(4):e528-30. [Epub ahead of print] – Senior Responsible Author (Impact Factor 1.643)
  26. Mazzarello S, Clemons M, Graham ID, Jacobs C. Surviving Surveys. J Oncol Pract. 2014 Aug 5. pii: JOP.2014.001484. [Epub ahead of print] PubMed PMID: 25095823. – Collaborator (Impact Factor NA)
  27. Ng TL, Clemons M, Hutton B, Dranistaris G. Aprepitant Versus Dexamethasone to Prevent Delayed Emesis After Chemotherapy. J Clin Oncol. 2014 Jun 9. pii:JCO.2014.55.3503. [Epub ahead of print] – Senior Responsible Author (Impact Factor 17.879)
  28. Clemons MJ, Cochrane B, Pond GR, Califaretti N, Chia SK, Dent RA, Song X, Robidoux A, Parpia S, Warr D, Rayson D, Pritchard KI, Levine MN. Randomised, phase II, placebo-controlled, trial of Fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Res Treat. 2014 Jun 13. [Epub ahead of print] – Senior Responsible Author (Impact Factor 4.198)
  29. Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Res Treat. 2014 Mar 18. [Epub ahead of print] – Senior Responsible Author (Impact Factor 5.881)
  30. Simos D, Hutton B, Graham ID, Arnaout A, Caudrelier JM, Mazzarello S, Clemons M. Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer. Springerplus. 2014;3:176. doi:10.1186/2193-1801-3-176 – Senior Responsible Author (Impact Factor NA)
  31. Simos D, Hutton B, Graham ID, Arnaout A, Caudrelier JM, Mazzarello S, Clemons M. Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer. Springerplus. 2014 Apr 5;3:176. – Senior Responsible Author (Impact Factor NA)
  32. Jacobs C, Simos D, Addison C, Ibrahim M, Clemons M. Pharmacotherapy of bone metastases in breast cancer patients - an update. Expert Opin Pharmacother. 2014;15(8):1109-18. – Senior Responsible Author (Impact Factor 3.085)
  33. Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncol Lett. 2014 Mar;7(3):866-870. Epub 2014 Jan 7. – Senior Responsible Author (Impact Factor 0.99)
  34. Saleh RR, Bouganim N, Hilton J, Arnaout A, Clemons M. Neoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again? Curr Oncol. 2014 Feb;21(1):e122-e128. – Senior Responsible Author (Impact Factor 1.643)
  35. Hilton J, Arnaout A, Clemons M. Primary endocrine therapy as an approach for patients with localized breast cancer deemed not to be surgical candidates. Curr Opin Support Palliat Care. 2014;8(1):53-8. – Senior Responsible Author (H index 22 )
  36. Jacobs C, Simos D, Clemons M. Treatment for locally advanced breast cancer: a global challenge, personalized medicine or both? Curr Opin Support Palliat Care. 2014;8(1):30-2. Senior Responsible Author (H index 22)
  37. Simos D, Clemons M, Ginsburg OM, Jacobs C. Definition and consequences of locally advanced breast cancer. Curr Opin Support Palliat Care. 2014;8(1):33-8 – Senior Responsible Author (H index 22)
  38. Beusterien K, Grinspan J, Kuchuk I, Mazzarello S, Dent S, Gertler S, Bouganim N, Vandermeer L, Clemons M. Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects. Oncologist. 2014;19(2):127-34. – Senior Responsible Author (Impact factor 4.540) 
  39. Kuchuk, I, Hutton, B, Moretto, P, Ng, T, Addison, C.L, Clemons, M. Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre. Journal of Bone Oncology 2(2013)137–144 – Senior Responsible Author (Impact factor NA)
  40. Hutton B, Addison C, Mazzarello S, Joy A, Bouganim N, Fergusson D, Clemons M. De-escalated Administration of Bone-Targeted Agents in Patients with Breast and Prostate Cancer - A Survey of Canadian Oncologists. Journal of Bone Oncology 2013;2(2): 77–83 – Senior Responsible Author (Impact factor NA)
  41. Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N. Investigating the discernible and distinct effects of platinum based chemotherapy regimens for metastatic triple negative breast cancer on time to progression. Online first. Oncology Letters – Collaborator (Impact Factor 0.2)
  42. Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, Dent SF, Song X, Segal R, Mazzarello S, Crawley F, Dranitsaris G, Clemons M. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat. 2013;142(1):101-7 – Senior Responsible Author (Impact Factor; 4.469)
  43. Hilton JF, Bouganim N, Dong B, Chapman JW, Arnaout A, O'Malley F, Gelmon KA, Yerushalmi R, Levine MN, Bramwell VH, Whelan TJ, Pritchard KI, Shepherd LE, Clemons M. Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials. Breast Cancer Res Treat. 2013;142(1):143-51– Senior Responsible Author (Impact Factor; 4.469)
  44. Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2013 Sep 25;15(5):R88. [Epub ahead of print] – Collaborator (Impact Factor of 5.87)
  45. Fralick M, Ray M, Fung C, Booth CM, Mallick R, Clemons MJ. Bevacizumab for Advanced Breast Cancer: Hope, Hype, and Hundreds of Headlines. The Oncologist. 2013;18(11):1174-9 – Senior Responsible Author (Impact factor 3.91)
  46. Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, Song X, Graham N, Dent S. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. Breast Cancer Res Treat. 2013;141(1):111-7 – Collaborator (impact factor 4.5)
  47. Clemons MJ, Vandermeer LA, Gunstone I, Jacobs C, Kaizer L, Paterson AH. Lost in Transition? Thoughts on Retirement, "Will You Still Need Me, Will You Still Feed Me, When I'm Sixty-Four?" The Oncologist 2013;18(11):1235-8 - Senior Responsible Author (Impact factor 3.91)
  48. Hutton B, Addison C, Campbell K, Fergusson D, Mazarello S, Clemons M. A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer. Journal of Bone Oncology, Published online first. 2013. – Senior Responsible Author (Impact factor NA)
  49. Russell K, Josse R, Paterson A, Amir E, Kuchuk I, Clemons M. Does Estrogen Play a Role in Response to Adjuvant Bone-Targeted Therapies? Journal of Bone Oncology, Published online first. 2013 – Senior Responsible Author (Impact factor NA)
  50. Kuchuk I, Mazzarello S, Butterfield K, Appleton A, Addison CL, Clemons M. Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists. Journal of Bone Oncology 2013;2:38–46. – Senior Responsible Author
  51. Hutton B, Morretto P, Emmenegger U, Mazarello S, Kuchuk I, Addison C, Clemons M. Bone-Targeted Agent Use For Bone Metastases From Breast Cancer and Prostate Cancer: A Patient Survey. Journal of Bone Oncology 2, Issue 3, 2013, 105-109 – Senior Responsible Author
  52. Bouganim N, Tsvetkova E, Clemons M, Amir E. Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat. 2013 Jun;139(2):603-6 – Collaborator (impact factor 4.5)
  53. Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P. Incidence and consequences of bone metastases in lung cancer patients. Journal of Bone Oncology 2013; 2(1): 22–29 – Collaborator 
  54. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. A prospective study evaluating the impact of tissue confirmation of metastatic disease in breast cancer patients. Journal of Clinical Oncology 2012;30(6):587-92 – Senior Responsible Author (Impact factor 17.7)
  55. Wheatley-Price P, Hutton B, Clemons M. Holiday reading: The Mayan Doomsday's effect on survival outcomes in clinical trials. CMAJ. 2012;184(18):2021-2.
  56. Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S, Wheatley-Price P, Milano C, Clemons M. Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. Curr Oncol. 2012;19(6):e414-21. – Senior Responsible Author (impact factor 1.6)
  57. Fralick M, Bouganim N, Kremer R, Kekre N, Robertson S, Vandermeer L, Kuchuk I, Li J, Murshed M, Clemons M. Histomorphometric and microarchitectural analyses using the 2mm bone marrow trephine in metastatic breast cancer patients - preliminary results. Journal of Bone Oncology Volume 1, Issue 3, 2012, Pages 69-73 – Senior Responsible Author
  58. Kuchuk I, Addison C, Simons D, Clemons M. A national portfolio of bone oncology trials - the Canadian experience in 2012. Journal of Bone Oncology Volume 1, Issue 3, December 2012, Pages 95-100 – Senior Responsible Author
  59. Mourskaia AA, Amir E, Dong Z, Tiedemann K, Cory S, Omeroglu A, Bertos N, Ouellet V, Clemons M, Scheffer GL, Park M, Hallett M, Komarova SV, Siegel PM. ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Res. 2012;14(6):R149. [Epub ahead of print] PubMed PMID: 23174366. – Collaborator(impact factor – 4.5)
  60. Kuchuk I, Clemons M, Addison C. Time to put an end to the "one size fits all" approach to bisphosphonate use in patients with metastatic breast cancer? Curr Oncol. 2012 Oct;19(5):e303-4 – Collaborator(impact factor 1.6)
  61. Clemons M, Gelmon KA, Pritchard KI, Paterson AHG. Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Current Oncology 16;5:2012, 259-268 – Senior Responsible Author (impact factor 1.6)
  62. Simmons CE, Kuchuk I, Freedman OC, Colgan T, Dodd A, Kulhanek K, Sheiner J,Dranitsaris G, Dowsett M, Folkerd E, Clemons MJ. Are Estring(®) and Vagifem(®) Equally Effective and Safe for the Treatment of Urogenital Atrophy in Breast Cancer Patients on Aromatase Inhibitor Therapy? Clin Oncol (R Coll Radiol);24(8):e128-9,2012 – Senior Responsible Author (impact factor – 2.9)
  63. Kuchuk, I, Paterson A, Amir, E, Clemons M, Bouganim N. Treatment recommendations for the use of bone-targeted agents in 2011- report from the 6th annual Bone and the Oncologist New Updates meeting. Current Oncology 2012; 19 (5) , pp. e364-e370 – Collaborator (impact factor – 1.6)
  64. Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer. Am J Clin Oncol. 2012 Jul 9. [Epub ahead of print] – Senior Responsible Author (impact factor – 2.5)
  65. Daneshmand M, Hanson JEL, Nabavi M, Hilton JF, Vandermeer L, Kanji F, Dent SF, Clemons M, Lorimer IAJ. Detection of PIK3CA Mutations in Breast Cancer Bone Metastases. ISRN Oncology, vol. 2012, Article ID 492578, 8 pages, 2012. doi:10.5402/2012/492578. - Collaborator
  66. Samiee S, Berardi P, Bouganim N, Vandermeer L, Arnaout A, Dent S, Mirsky D, Chasen M, Caudrelier JM, Clemons M. Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemma. Curr Oncol. 2012;19(4):e270-9. – Senior Responsible Author (impact factor – 1.6)
  67. Zhu X, Bouganim N, Vandermeer L, Dent SF, Dranitsaris G, Clemons MJ. Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience. Curr Oncol. 2012;19(4):e239-43. – Senior Responsible Author (impact factor – 1.6)
  68. Granek L, Fitzgerald B, Fergus K, Clemons M, Heisey R. Travelling on parallel tracks: patient and physician perspectives on why women delay seeking care for breast cancer symptoms. Can Oncol Nurs J. 2012 Spring;22(2):101-13. English, French. – Collaborator
  69. Dranitsaris G, Bouganim N, Milano C, Vandermeer L, Dent S, Wheatley-Price P, Laporte J, Oxborough KA, Clemons M. Prospective Validation of a Prediction Tool for Identifying Patients at High Risk for Chemotherapy-Induced Nausea and Vomiting. J Support Oncol. 2012;19(6):e414-21 – Senior Responsible Author
  70. Fralick M, Hilton JF, Bouganim N, Clemons M, Amir E. Dual Blockade of HER2 - Twice as Good or Twice as Toxic? Clin Oncol (R Coll Radiol). 2012;24(9):593-603. – Collaborator (impact factor 2.8)
  71. Ginsburg OM, Hanna TP, Vandenberg T, Joy AA, Clemons M, Game M, Maccormick R, Elit LM, Rosen B, Rahim Y, Geddie W, Sutcliffe SB, Gospodarowicz M. The global cancer epidemic: opportunities for Canada in low- and middle-income countries. CMAJ. 2012 Oct 16;184(15):1699-704 – Collaborator (Impact factor 9)
  72. Lee G, Clemons M, Cho J, Czarnota GJ, Dinniwell R. Caught in the middle: case study of a brachial (sentry) lymph node recurrence after resection and locoregional breast radiotherapy. Curr Oncol. 2012 Jun;19(3):e211-5 – Collaborator (Impact factor 1.8)
  73. Clemons M, Russell K. Costa L, Addison CL. Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated? Breast Cancer Research and Treatment 2012 Jul;134(2):453-7 – Senior Responsible Author (Impact factor 4.8)
  74. Young SD, Lafrenie RM, Clemons MJ. Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer. Curr Oncol. 2012;19(2):e75-83. – Collaborator (Impact factor 1.8)
  75. Tabariès S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J, Ferri LE, Omeroglu A, Basik M, Amir E, Clemons M, Siegel PM. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol. 2012;32(15):2979-91 – Collaborator (Impact factor 6)
  76. Russell K, Clemons M, Costa L, Addison CL. Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there? Journal of Bone Oncology 2012;1(1): 12-17 – Collaborator
  77. Boileau JF, Simmons C, Clemons M, Gandi S, Lee J, Chia SK, Basik M, Provencher L, Untch M, Brackstone M. Extending neoadjuvant care through multi-disciplinary collaboration: proceedings from the Canadian Consortium for Locally Advanced Breast Cancer. Current Oncology 19;106-14, 2012 – Collaborator (Impact factor 1.8)